AADI BIOSCIENCE INC (AADI) Stock Price, Quote, News and Overview
NASDAQ:AADI - Nasdaq - US00032Q1040 - Common Stock - Currency: USD
AADI Quote, Performance and Key Statistics
NASDAQ:AADI (2/21/2025, 8:00:00 PM)
2.79
-0.07 (-2.45%)
The current stock price of AADI is 2.79 USD. In the past month the price decreased by -7.92%. In the past year, price increased by 46.84%.
AADI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AADI
Company Profile
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. The company has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Company Info
AADI BIOSCIENCE INC
17383 Sunset Avenue, Suite A250
Pacific Palisades CALIFORNIA US
CEO: Joseph Gardner
Employees: 70
Company Website: https://aadibio.com/
Investor Relations: https://ir.aadibio.com/
Phone: 14244738055
AADI BIOSCIENCE INC / AADI FAQ
What is the stock price of AADI BIOSCIENCE INC today?
The current stock price of AADI is 2.79 USD. The price decreased by -2.45% in the last trading session.
What is the ticker symbol for AADI BIOSCIENCE INC stock?
The exchange symbol of AADI BIOSCIENCE INC is AADI and it is listed on the Nasdaq exchange.
On which exchange is AADI stock listed?
AADI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AADI BIOSCIENCE INC stock?
8 analysts have analysed AADI and the average price target is 3.06 USD. This implies a price increase of 9.68% is expected in the next year compared to the current price of 2.79. Check the AADI BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AADI BIOSCIENCE INC worth?
AADI BIOSCIENCE INC (AADI) has a market capitalization of 68.86M USD. This makes AADI a Micro Cap stock.
How many employees does AADI BIOSCIENCE INC have?
AADI BIOSCIENCE INC (AADI) currently has 70 employees.
What are the support and resistance levels for AADI BIOSCIENCE INC (AADI) stock?
AADI BIOSCIENCE INC (AADI) has a support level at 2.63 and a resistance level at 2.88. Check the full technical report for a detailed analysis of AADI support and resistance levels.
Is AADI BIOSCIENCE INC (AADI) expected to grow?
The Revenue of AADI BIOSCIENCE INC (AADI) is expected to grow by 7.3% in the next year. Check the estimates tab for more information on the AADI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AADI BIOSCIENCE INC (AADI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AADI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AADI, evaluating the profitability, health, valuation and growth aspects
- AADI BIOSCIENCE INC (AADI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AADI BIOSCIENCE INC (AADI) Sales and EPS estimates to see what analysts future expectations are.
- AADI BIOSCIENCE INC (AADI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AADI BIOSCIENCE INC (AADI) Insider and Institutional Ownership to learn about the owners and their transactions.
- AADI BIOSCIENCE INC (AADI) Stock Chart to make your own analysis
- AADI BIOSCIENCE INC (AADI) Latest news and press-releases to stay up to date.
Does AADI BIOSCIENCE INC (AADI) stock pay dividends?
AADI does not pay a dividend.
When does AADI BIOSCIENCE INC (AADI) report earnings?
AADI BIOSCIENCE INC (AADI) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of AADI BIOSCIENCE INC (AADI)?
AADI BIOSCIENCE INC (AADI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.28).
What is the Short Interest ratio of AADI BIOSCIENCE INC (AADI) stock?
The outstanding short interest for AADI BIOSCIENCE INC (AADI) is 3.23% of its float. Check the ownership tab for more information on the AADI short interest.
AADI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AADI. When comparing the yearly performance of all stocks, AADI is one of the better performing stocks in the market, outperforming 91.58% of all stocks.
AADI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AADI. The financial health of AADI is average, but there are quite some concerns on its profitability.
AADI Financial Highlights
Over the last trailing twelve months AADI reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS increased by 3.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.98% | ||
| ROE | -89.57% | ||
| Debt/Equity | 0 |
AADI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to AADI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 7.2% and a revenue growth 7.3% for AADI